Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QNWS | ISIN: NL00150005Y4 | Ticker-Symbol: 9EN
Tradegate
06.06.25 | 20:50
14,900 Euro
+2,05 % +0,300
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARVARIS NV Chart 1 Jahr
5-Tage-Chart
PHARVARIS NV 5-Tage-Chart
RealtimeGeldBriefZeit
14,30014,70006.06.
14,30014,90006.06.

Aktuelle News zur PHARVARIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCitizens JMP bekräftigt "Market Outperform"-Rating für Pharvaris-Aktie1
DoCitizens JMP reiterates Market Outperform rating for Pharvaris stock1
MoPharvaris N.V.: Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema1
19.05.Pharvaris N.V.: Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses3
14.05.Pharvaris GAAP EPS of -€0.851
13.05.Pharvaris N.V.: Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update296Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal...
► Artikel lesen
13.05.Pharvaris N.V. - 6-K, Report of foreign issuer-
PHARVARIS Aktie jetzt für 0€ handeln
12.05.Pharvaris N.V.: Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 41
23.04.JMP reiterates Pharvaris stock with $55 target, positive outlook2
07.04.Pharvaris GAAP EPS of -€0.641
07.04.Pharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update108Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3...
► Artikel lesen
07.04.Pharvaris N.V. - 6-K, Report of foreign issuer-
07.04.Pharvaris N.V. - 20-F, Annual and transition report of foreign private issuers-
02.04.EC grants orphan designation for Pharvaris' deucrictibant drug1
01.04.Pharvaris N.V.: Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission157ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet...
► Artikel lesen
03.03.Pharvaris meldet anhaltende Reduktion der HAE-Anfallsrate2
03.03.Pharvaris N.V.: Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress117Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1...
► Artikel lesen
03.03.Citizens JMP maintains $55 target on Pharvaris stock, upbeat on deucrictibant1
18.02.JMP Securities maintains Pharvaris stock with $55 target2
31.01.Why Pharvaris (PHVS) Is Advancing Today1
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1